New CLA3+/4 scores predict outcomes in MASLD.
BACKGROUND & AIMS Fibrosis is a major determinant of adverse outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We developed and validated two probability scores for advanced fibrosis (≥F3) and cirrhosis (F4)-CLA3+ and CLA4-using controlled attenuation parameter (CAP), liver stiffness (LS) by...